Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts (ALC) in Patients With Sepsis

NCT03821038 is registered in ClinicalTrials.gov with Revimmune as lead sponsor.

NCT NCT03821038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03821038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts (ALC) in Patients With Sepsis
Lead sponsor
Revimmune
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2019
Completion date
October 6, 2021
Enrollment
21 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis, severe